The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
AKERO THERAPEUTICS INC COM 00973Y108 70,909 2,444,311 SH   SOLE   2,444,311 0 0
ALX ONCOLOGY HLDGS INC COM 00166B105 715,272 9,699,925 SH   SOLE   9,699,925 0 0
APELLIS PHARMACEUTICALS INC COM 03753U106 21,046 490,471 SH   SOLE   490,471 0 0
CHECKMATE PHARMACEUTICALS IN COM 162818108 44,595 3,673,374 SH   SOLE   3,673,374 0 0
HARMONY BIOSCIENCES HLDGS IN COM 413197104 115,793 3,504,624 SH   SOLE   3,504,624 0 0
METACRINE INC COM 59101E103 18,967 3,059,123 SH   SOLE   3,059,123 0 0
PHARVARIS N V COM N69605108 64,447 2,303,310 SH   SOLE   2,303,310 0 0
VERONA PHARMA PLC SPONSORED ADS 925050106 1,353 161,897 SH   SOLE   161,897 0 0